List view / Grid view
Dr Ronald G Crystal, Professor and Chairman of the Department of Genetic Medicine, Weill Cornell Medical College, spoke to Drug Target Review’s Fraser Owen about his research into Alzheimer’s disease and why gene therapies represent a promising area of research for neurodegenerative conditions.
Scientists have developed a new strategy using brain-wide genome-editing technology that reduced Alzheimer’s disease pathologies in mice.
Researchers have created a new method to quantify protein droplets involved in neurodegenerative diseases, enhancing the study of treatments.
Scientists used a synthetic thyroid hormone in mice to regulate the TREM2 gene implicated in diseases such as Alzheimer’s and Parkinson’s.
Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
Scientists have shown that manipulating the perineuronal nets (PNNs) in the brains of mice led to the reversal of age-related memory loss.
A non-invasive, label-free optical method can produce high-resolution imaging of cellular brain diseases in vivo.
Promising results have been shown in an animal model of Alzheimer's disease treated with zinc finger protein transcription factors.
Scientists have developed a model of the early stages of Alzheimer's disease in rhesus macaques to better test new treatments.
Researchers have developed a new tool that can add or remove sugar from proteins, which could be used to treat currently "undruggable" targets.
Researchers have used artificial intelligence to screen 80 FDA-approved drugs and reveal which could be used as Alzheimer's treatments.
Using X-ray crystallography and cryo-electron microscopy, researchers have elucidated the structure of the SARM1 protein, a target for neurodegeneration.
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
Researchers have found that the spasmolytic drug hymecromone can suppress astrocyte inflammatory responses, meaning it could be used to combat Alzheimer's disease.
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.
